Phospho-NF kappaB p100/p52 (Ser872) Antibody - #AF3375
Product: | Phospho-NF kappaB p100/p52 (Ser872) Antibody |
Catalog: | AF3375 |
Description: | Rabbit polyclonal antibody to Phospho-NF kappaB p100/p52 (Ser872) |
Application: | WB IF/ICC |
Reactivity: | Human, Mouse |
Prediction: | Pig, Bovine, Horse, Sheep, Rabbit, Dog |
Mol.Wt.: | 100kDa; 97kD(Calculated). |
Uniprot: | Q00653 |
RRID: | AB_2834806 |
Product Info
*The optimal dilutions should be determined by the end user.
*Tips:
WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.
Cite Format: Affinity Biosciences Cat# AF3375, RRID:AB_2834806.
Fold/Unfold
CVID10; DNA binding factor KBF2; H2TF1; Lymphocyte translocation chromosome 10 protein; LYT 10; NF kB2; NFKB p52/p100 subunit; Nuclear factor Kappa B subunit 2; Nuclear factor of kappa light polypeptide gene enhancer in B cells 2 (p49/p100); Nuclear factor of kappa light polypeptide gene enhancer in B cells 2; Oncogene Lyt 10; p100; Transcription factor NFKB2;
Immunogens
- Q00653 NFKB2_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MESCYNPGLDGIIEYDDFKLNSSIVEPKEPAPETADGPYLVIVEQPKQRGFRFRYGCEGPSHGGLPGASSEKGRKTYPTVKICNYEGPAKIEVDLVTHSDPPRAHAHSLVGKQCSELGICAVSVGPKDMTAQFNNLGVLHVTKKNMMGTMIQKLQRQRLRSRPQGLTEAEQRELEQEAKELKKVMDLSIVRLRFSAFLRASDGSFSLPLKPVISQPIHDSKSPGASNLKISRMDKTAGSVRGGDEVYLLCDKVQKDDIEVRFYEDDENGWQAFGDFSPTDVHKQYAIVFRTPPYHKMKIERPVTVFLQLKRKRGGDVSDSKQFTYYPLVEDKEEVQRKRRKALPTFSQPFGGGSHMGGGSGGAAGGYGGAGGGGSLGFFPSSLAYSPYQSGAGPMGCYPGGGGGAQMAATVPSRDSGEEAAEPSAPSRTPQCEPQAPEMLQRAREYNARLFGLAQRSARALLDYGVTADARALLAGQRHLLTAQDENGDTPLHLAIIHGQTSVIEQIVYVIHHAQDLGVVNLTNHLHQTPLHLAVITGQTSVVSFLLRVGADPALLDRHGDSAMHLALRAGAGAPELLRALLQSGAPAVPQLLHMPDFEGLYPVHLAVRARSPECLDLLVDSGAEVEATERQGGRTALHLATEMEELGLVTHLVTKLRANVNARTFAGNTPLHLAAGLGYPTLTRLLLKAGADIHAENEEPLCPLPSPPTSDSDSDSEGPEKDTRSSFRGHTPLDLTCSTKVKTLLLNAAQNTMEPPLTPPSPAGPGLSLGDTALQNLEQLLDGPEAQGSWAELAERLGLRSLVDTYRQTTSPSGSLLRSYELAGGDLAGLLEALSDMGLEEGVRLLRGPETRDKLPSTAEVKEDSAYGSQSVEQEAEKLGPPPEPPGGLCHGHPQPQVH
Predictions
Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.
High(score>80) Medium(80>score>50) Low(score<50) No confidence
PTMs - Q00653 As Substrate
Site | PTM Type | Enzyme | Source |
---|---|---|---|
K19 | Sumoylation | Uniprot | |
S22 | Phosphorylation | Uniprot | |
S23 | Phosphorylation | Uniprot | |
K28 | Ubiquitination | Uniprot | |
K47 | Ubiquitination | Uniprot | |
Y55 | Phosphorylation | Uniprot | |
K72 | Ubiquitination | Uniprot | |
K90 | Sumoylation | Uniprot | |
T97 | Phosphorylation | Uniprot | |
S99 | Phosphorylation | O15111 (CHUK) | Uniprot |
S108 | Phosphorylation | O15111 (CHUK) | Uniprot |
K112 | Ubiquitination | Uniprot | |
S115 | Phosphorylation | O15111 (CHUK) | Uniprot |
S123 | Phosphorylation | O15111 (CHUK) | Uniprot |
K143 | Ubiquitination | Uniprot | |
K144 | Ubiquitination | Uniprot | |
K153 | Ubiquitination | Uniprot | |
S161 | Phosphorylation | Uniprot | |
T167 | Phosphorylation | Uniprot | |
K179 | Ubiquitination | Uniprot | |
S204 | Phosphorylation | Uniprot | |
S222 | Phosphorylation | P49841 (GSK3B) | Uniprot |
K229 | Ubiquitination | Uniprot | |
K235 | Ubiquitination | Uniprot | |
K252 | Ubiquitination | Uniprot | |
S277 | Phosphorylation | Uniprot | |
Y285 | Phosphorylation | Uniprot | |
K298 | Sumoylation | Uniprot | |
K321 | Ubiquitination | Uniprot | |
Y325 | Phosphorylation | Uniprot | |
Y326 | Phosphorylation | Uniprot | |
K332 | Ubiquitination | Uniprot | |
T429 | Phosphorylation | Uniprot | |
T651 | Phosphorylation | Uniprot | |
T655 | Phosphorylation | Uniprot | |
T682 | Phosphorylation | Uniprot | |
K689 | Sumoylation | Uniprot | |
S707 | Phosphorylation | P49841 (GSK3B) | Uniprot |
S711 | Phosphorylation | P49841 (GSK3B) | Uniprot |
S713 | Phosphorylation | Uniprot | |
S715 | Phosphorylation | Uniprot | |
S717 | Phosphorylation | Uniprot | |
S727 | Phosphorylation | Uniprot | |
S739 | Phosphorylation | Uniprot | |
K741 | Ubiquitination | Uniprot | |
K743 | Ubiquitination | Uniprot | |
S762 | Phosphorylation | Uniprot | |
S802 | Phosphorylation | Uniprot | |
S812 | Phosphorylation | Uniprot | |
K855 | Ubiquitination | Uniprot | |
S858 | Phosphorylation | Uniprot | |
T859 | Phosphorylation | Uniprot | |
K863 | Sumoylation | Uniprot | |
S866 | Phosphorylation | Q99558 (MAP3K14) | Uniprot |
Y868 | Phosphorylation | Uniprot | |
S870 | Phosphorylation | Q99558 (MAP3K14) | Uniprot |
S872 | Phosphorylation | O15111 (CHUK) | Uniprot |
Research Backgrounds
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer.
While translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p52 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.
Subsequent to MAP3K14-dependent serine phosphorylation, p100 polyubiquitination occurs then triggering its proteasome-dependent processing.
Constitutive processing is tightly suppressed by its C-terminal processing inhibitory domain, named PID, which contains the death domain.
Nucleus. Cytoplasm.
Note: Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).
Component of the NF-kappa-B RelB-p52 complex. Homodimer; component of the NF-kappa-B p52-p52 complex. Component of the NF-kappa-B p65-p52 complex. Component of the NF-kappa-B p52-c-Rel complex. NFKB2/p52 interacts with NFKBIE. Component of a complex consisting of the NF-kappa-B p50-p50 homodimer and BCL3. Directly interacts with MEN1.
The C-terminus of p100 might be involved in cytoplasmic retention, inhibition of DNA-binding by p52 homodimers, and/or transcription activation.
The glycine-rich region (GRR) appears to be a critical element in the generation of p52.
Research Fields
· Environmental Information Processing > Signal transduction > MAPK signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > NF-kappa B signaling pathway. (View pathway)
· Human Diseases > Infectious diseases: Bacterial > Legionellosis.
· Human Diseases > Infectious diseases: Viral > HTLV-I infection.
· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.
· Human Diseases > Cancers: Overview > Pathways in cancer. (View pathway)
· Human Diseases > Cancers: Overview > Viral carcinogenesis.
· Human Diseases > Cancers: Specific types > Breast cancer. (View pathway)
· Organismal Systems > Development > Osteoclast differentiation. (View pathway)
Restrictive clause
Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.
For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.